comparemela.com
Home
Live Updates
Eisai: LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimers Disease in China -January 09, 2024 at 10:22 pm EST : comparemela.com
Eisai: "LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in China -January 09, 2024 at 10:22 pm EST
- Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta monoclonal antibody LEQEMBI has been approved in China as a treatment of mild cognitive...
Related Keywords
China ,
Tabeta ,
Mie ,
Japan ,
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Tokyo ,
Japanese ,
Jack Cox ,
Biogen Inc ,
Eisai Co Ltd ,
Public Relations Department ,
Nasdaq ,
Jd Health ,
England Journal ,
Health Industry Development Limited Company ,
Japan Corporate News ,
Markets ,
comparemela.com © 2020. All Rights Reserved.